PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE
| Autor: | A Urspruch, P Marcellin, K Papadakis, DM Jensen, D Tonev |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Oncology
medicine.medical_specialty Cost effectiveness business.industry Health Policy Ribavirin Perspective (graphical) Public Health Environmental and Occupational Health Virology chemistry.chemical_compound stomatognathic diseases chemistry Internal medicine Genotype Hcv treatment medicine business health care economics and organizations Peginterferon alfa-2a medicine.drug |
| Zdroj: | Value in Health. (7):A427 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/S1098-3015(10)75111-1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|